# US 9,433,689 B2 · Probes and methods of imaging non-Hodgkins lymphoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,433,689 B2
- Document ID: US9433689B2
- Status: Granted
- Kind: B2
- Application number: 14/204,039
- Filed: 2014-03-11
- Published: 2014-09-18
- Granted: 2016-09-06
- Earliest claimed: 2013-03-12
- Assignees: The Board of Trustees of the Leland Stanford Junio
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Benjamin Hackel; Arutselvan Natarajan; Sanjiv S. Gambhir
- Web page: https://patentgrep.com/patent/US9433689B2

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Embodiments of the present disclosure provide for labeled probes such as a 64Cu-FN3 probe (FN3 refers to fibronectin type 3 domain); methods of making labeled probes; pharmaceutical compositions including labeled probes; methods of using labeled probes; methods of diagnosing, localizing, monitoring, and/or assessing non-Hodgkin's lymphoma, cancers, tumors, precancerous cells, and related biological events using labeled probes; kits for diagnosing, localizing, monitoring, and/or assessing non-Hodgkin's lymphoma, cancers, tumors, precancerous cells, and related biological events; and the like.

## Claims

### Claim 1

A method of diagnosing the presence of a non-Hodgkin's lymphoma in a subject, the method comprising:
administering to the subject a labeled probe with a sequence having SEQ. ID. NO.: 2 or SEQ. ID. NO.: 4, wherein the probe binds to a CD20 protein;
imaging at least a portion of the subject; and
detecting the labeled probe, wherein the location of the labeled probe corresponds to the location of the non-Hodgkin's lymphoma.

### Claim 2 (depends on 1)

The method of claim 1, wherein the labeled probe includes a metal selected from the group consisting of: 64Cu, 89Zr, 86Y and 68Ga, and is conjugated with the sequence.

### Claim 3 (depends on 2)

The method of claim 2, wherein the metal is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.

### Claim 4 (depends on 2)

The method of claim 2, wherein at least two metals are conjugated to the sequence.

### Claim 5 (depends on 2)

The method of claim 2, wherein the metal is conjugated to the sequence using a chelator selected from the group consisting of: DOTA, NOTA, EDTA, desferrioxamine (Df), DTPA, and TETA.

### Claim 6 (depends on 5)

The method of claim 5, wherein the metal is 64Cu and the chelator is DOTA.

### Claim 7 (depends on 1)

The method of claim 1, wherein the metal is 64Cu and is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.

### Claim 8

A method of monitoring the progress of a non-Hodgkin's lymphoma in a subject, the method comprising:
administering to the subject a labeled probe with a sequence having SEQ. ID. NO.: 2 or SEQ. ID. NO.: 4, wherein the probe binds to a CD20 protein;
imaging at least a portion of the subject; and
detecting the labeled probe, wherein location of the labeled probe corresponds to the location of the non-Hodgkin's lymphoma, wherein the location is monitored.

### Claim 9 (depends on 8)

The method of claim 8, further comprising repeating the steps of claim 8 to monitor the location corresponding to the non-Hodgkin's lymphoma.

### Claim 10 (depends on 8)

The method of claim 8, wherein the labeled probe includes a metal selected from the group consisting of: 64Cu, 89Zr, 86Y and 68Ga, and is conjugated with the sequence.

### Claim 11 (depends on 10)

The method of claim 10, wherein the metal is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.

### Claim 12 (depends on 10)

The method of claim 10, wherein at least two metals are conjugated to the sequence.

### Claim 13 (depends on 10)

The method of claim 10, wherein the metal is conjugated to the sequence using a chelator selected from the group consisting of: DOTA, NOTA, EDTA, Df, DTPA, and TETA.

### Claim 14 (depends on 13)

The method of claim 13, wherein the metal is 64Cu and the chelator is DOTA.

### Claim 15 (depends on 10)

The method of claim 10, wherein the metal is 64Cu and is conjugated to the sequence via a lysine amino acid or a N-terminus free amine site.

### Claim 16 (depends on 1)

The method of claim 1, wherein the sequence is SEQ. ID. NO.: 2.

### Claim 17 (depends on 1)

The method of claim 1, wherein the sequence is SEQ. ID. NO.: 4.

### Claim 18 (depends on 8)

The method of claim 8, wherein the sequence is SEQ. ID. NO.: 2.

### Claim 19 (depends on 8)

The method of claim 8, wherein the sequence is SEQ. ID. NO.: 4.